Frontiers in Psychiatry
2025
Rayyan Raja Zafar, Patrick Kleine, Danielle Kurtin et al.
Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This paper calls for a reorientation of...
Frontiers in Psychiatry
2025
Scott Matthews, Antonino Greco, Clara Rastelli et al.
1 citation
Psychedelic-assisted therapy is a remarkably promising treatment for substance use disorders and for alcohol use disorder (AUD) in particular. Research supporting psychedelics as a safe and effective pharmacotherapy for AUD and its comorbid psychiatric conditions dates from the late1940s and includes over 2,000 published studies. There are, however, challenges to the clinical implementation of...
Ketamine
2025
Katarina Savić Vujović, Ana Jotić, Branislava Medić et al.
1 citation
Substance use disorders (SUDs), including alcohol, opioid, and cocaine dependencies, present significant challenges in public health. Current treatment modalities often face limitations in efficacy and accessibility, necessitating exploration of novel therapeutic approaches. Ketamine, originally recognized for its anesthetic properties, has garnered attention for its potential in treating SUDs...
Medical Research Archives
2025
Matthew Halma, Joseph Varón, Sirjana Dhillon et al.
Psychedelic therapies have emerged as a modality of treatment for several treatment resistant diseases, including post-traumatic stress disorder (PTSD), treatment resistant depression, substance use disorders, anxiety, and obsessive-compulsive disorders. Arguably more than with other therapies, their success is dependent on the facilitator and the context of the administration. Several programs...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Medical Research Archives
2025
Mustafa Zaman, Aseel Aljeshi, Kuragamage Kuraga et al.
1 citation
The use of drugs for recreational purposes has changed dramatically, involving a variety of substances such as opioids, hallucinogens, and cannabinoids. Although these substances are often initially used for recreational purposes, their psychoactive properties can contribute to the development of addiction, withdrawal syndromes, and significant physical and mental health complications. The...
Annales pharmaceutiques francaises
2025
Olivier Pierrefiche
Alcohol consumption is a major public health issue. Patients with Alcohol Use Disorder (AUD) can benefit from five treatments that preferentially target membrane receptors, and whose efficacy is generally modest. However, a large body of experimental evidence points to an important role for epigenetics in the effects of alcohol consumption, and epidrugs that modify the epigenome offer an...
PLoS One
2025
Masume Bakhtiari, Mojtaba Habibi Asgarabad, Fahimeh Dehghani et al.
6 citations
Adolescents with Internet addiction (IA) frequently encounter elevated levels of anxiety and depression, which subsequently results in the perpetuation of their addiction behaviors. Mindfulness-based cognitive therapy for children (MBCT-C) is an adapted version of traditional MBCT that targets emotional problems in children. The present study aimed to provide a framework for the implementation...
PLoS One
2025
Jizhao Li, Dongling Wang, Shuang Bai et al.
6 citations
Mindfulness-based Tai Chi Chuan (MTCC) have been shown to contribute to improvements in cognitive and executive functions. Changes in inhibition, an aspect of executive function, have been closely linked to mobile phone addiction. However, the relationship between these elements remains unclear. This study aims to investigate the effects of an 8-week MTCC intervention on executive function,...
Frontiers in Psychology
2025
Diane Joss, Joseph Rosansky, Paula Gardiner et al.
1 citation
Adverse childhood experiences (ACE) are transdiagnostic developmental risk factors for various mental and physical health issues, including Opioid Use Disorder (OUD). Existing research demonstrated ACE not only affects the onset, severity, and comorbidity of disorders, but also affects treatment responses. To investigate whether and how ACE modulates treatment effects of Mindfulness Based...